FUCASO: The Revolutionary Fully-Human BCMA CAR-T Therapy with Unmatched Efficacy and Safety
product detail
FUCASO, developed by Nanjing IASO Biotechnology, is a groundbreaking CAR-T therapy specifically designed to target B-cell maturation antigen (BCMA). This therapy stands out for its unparalleled clinical efficacy and safety profile, providing a new hope for patients with relapsed or refractory multiple myeloma (r/rMM). Approved by the National Medical Products Administration (NMPA) on June 30, 2023, FUCASO has already demonstrated significant success in clinical applications.
Key Advantages of FUCASO
High Response Rates: FUCASO boasts an Overall Response Rate (ORR) of 98.9% and a Complete Response (CR) rate of 82.4%, significantly higher than other available treatments.
Durable Remission: Patients treated with FUCASO have shown a 12-month Progression-Free Survival (PFS) rate of 85.5%, indicating long-term remission and improved quality of life.
Safety Profile: With ≥3 grade Cytokine Release Syndrome (CRS) occurring in only 1% of patients and no reported cases of ≥3 grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), FUCASO offers a safer treatment option compared to other CAR-T therapies.
Cost-Effectiveness: FUCASO treatment costs significantly less than similar therapies available in the United States, making it a viable option for a broader range of patients.
Global Reach: IASO BIO has established a comprehensive treatment center network in China, capable of serving patients from around the world with integrated services from consultation to post-treatment care.
Clinical Success
The first patient treated with FUCASO has achieved five years of cancer-free survival, a remarkable milestone compared to the median Progression-Free Survival (PFS) of just 2.9 months with standard care. This highlights FUCASO's potential to transform the treatment landscape for multiple myeloma.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.